Oncotherapeutics

Oncotherapeutics is a privately held, US-based Contract Research Organization (CRO) founded in 2009, specializing in oncology and hematology clinical trials. Unlike large, generalized CROs, it has carved a strategic niche by exclusively partnering with community oncology clinics, enabling faster patient enrollment and real-world evidence generation. The company provides comprehensive clinical trial management services, from study design to execution and publication, aiming to optimize cancer treatments and improve patient access to cutting-edge trials. Its business model is service-based, generating revenue from pharmaceutical, biotech, and diagnostic partners.

Operational platform centered on a proprietary network of community-based hematology/oncology research sites, enabling accelerated patient enrollment, real-world evidence generation, and streamlined clinical trial execution for Phase 1-4 studies.

Oncotherapeutics competes in the fragmented CRO market, primarily against large, full-service global CROs (e.g., IQVIA, ICON) and other niche oncology CROs. Its key competitive differentiator is its exclusive focus on and deep integration with community oncology sites, a niche often underserved by larger players who prioritize academic centers.